Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells.
Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells.
复制标题
间充质干细胞治疗缺血性疾病的进展。
DOI：
10.1155/2016/5896061
复制
发表时间：
2016
影响因子：
4.3
通讯作者：
Li Q
中科院分区：
文献类型：
--
作者：
Li S;Wang X;Li J;Zhang J;Zhang F;Hu J;Qi Y;Yan B;Li Q
缺血性疾病是一组疾病，包括缺血性脑血管疾病、缺血性心肌病(ICM)、糖尿病足等，正成为全球发病率和死亡率的主要原因。间充质干细胞(MSCs)已在动物模型和临床试验中用于治疗各种缺血性疾病。大量近期文献表明，骨髓间充质干细胞治疗缺血性疾病是一种安全、有效的治疗方法。然而，影响治疗效果的因素很多，包括给药途径、MSCs在体内的存活率和住院率、移植时机、特殊的微环境以及患者的临床情况。本文就骨髓间充质干细胞治疗缺血性脑血管病、ICM和糖尿病足的现状、治疗潜力和影响因素进行了综述。我们认为，骨髓间充质干细胞移植将成为治疗缺血性疾病的理想选择。
Ischemic diseases are a group of diseases, including ischemic cerebrovascular disease, ischemic cardiomyopathy (ICM), and diabetic foot as well as other diseases which are becoming a leading cause of morbidity and mortality in the whole world. Mesenchymal stem cells (MSCs) have been used to treat a variety of ischemic diseases in animal models and clinical trials. Lots of recent publications demonstrated that MSCs therapy was safe and relieved symptoms in patients of ischemic disease. However, many factors could influence therapeutic efficacy including route of delivery, MSCs' survival and residential rate in vivo, timing of transplantation, particular microenvironment, and patient's clinical condition. In this review, the current status, therapeutic potential, and the detailed factors of MSCs-based therapeutics for ischemic cerebrovascular disease, ICM, and diabetic foot are presented and discussed. We think that MSCs transplantation would constitute an ideal option for patients with ischemic diseases.